pantothenate kinase 2
Last updated 18 Apr 2023
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The PANK2 gene provides instructions for making an enzyme called pantothenate kinase 2. This enzyme is active in specialized cellular structures called mitochondria, which are the cell's energy-producing centers. Within mitochondria, pantothenate kinase 2 regulates the formation of a molecule called coenzyme A. Coenzyme A is found in all living cells, where it is essential for the body's production of energy from carbohydrates, fats, and some protein building blocks (amino acids).
Video picks for GenesVideo library
Normal function
The PANK2 gene provides instructions for making an enzyme called pantothenate kinase 2. This enzyme is active in specialized cellular structures called mitochondria, which are the cell's energy-producing centers. Within mitochondria, pantothenate kinase 2 regulates the formation of a molecule called coenzyme A. Coenzyme A is found in all living cells, where it is essential for the body's production of energy from carbohydrates, fats, and some protein building blocks (amino acids).
PANK2 is one of four human genes that provide instructions for making versions of pantothenate kinase. The functions of these different versions probably vary among tissue types and parts of the cell. The version produced by the PANK2 gene is active in cells throughout the body, including nerve cells in the brain.
Conditions referring to this gene or chromosome
Other names
NBIA1
PANK2_HUMAN
pantothenate kinase 2 (Hallervorden-Spatz syndrome)
pantothenic acid kinase
Patient picks for Genes

PID Q&A
How do you contract PID?
Dr Sarah Jarvis MBE It is not known how many women develop PID each year, and it is probably often not picked up. It most commonly develops in women aged between 15 and 24 years. [https://patient.info/health/pelvic-pain-in-women/pelvic-inflammatory-disease#nav-2](https://patient.info/health/pelvic-pain-in-women/pelvic-inflammatory-disease#nav-2)
by Dr Sarah Jarvis

Allergies
How do hay fever tablets work?
Dr Sarah Jarvis MBE If your hay fever symptoms are not controlled on the medication that you are taking after 2-4 weeks, you should discuss this with your doctor. You may need to try a different treatment or add in another treatment. If you are taking hay fever medication regularly and your hay fever is well controlled on your current treatment, you should continue this treatment until the end of the pollen season. [https://patient.info/health/hay-fever-leaflet#nav-5](https://patient.info/health/hay-fever-leaflet#nav-5)
by Dr Sarah Jarvis

Sickness
When do I need a chest X-Ray if I have a cough?
Dr Sarah Jarvis MBE The doctor will want to know how long your cough has lasted and whether you have any other symptoms. The doctor will particularly ask about symptoms which may suggest an underlying serious condition ('red flags'). [https://patient.info/health/cough-leaflet#nav-2](https://patient.info/health/cough-leaflet#nav-2)
by Dr Sarah Jarvis

Video
What are the different kinds of vulvar problems?
Dr Lesley Regan There are many different conditions that can affect your vulva, ranging from mild infections to skin conditions and, very rarely, to cancer. They can all cause very different symptoms, including itching, bleeding, rashes or a lump. It is very important that if you notice any new symptoms or lumps in your vulval region then you see a doctor promptly. Your doctor will be able to examine you and decide which treatment will be appropriate to you. This will depend on the underlying cause of your symptoms. https://patient.info/health/vulval-problems-leaflet#nav-2
by Prof Lesley Regan, FRCOG

Contraceptive pills and patches
What are the side effects of the birth control patch?
Dr Rosemary Leonard Some women have skin irritation when they use the contraceptive patch. This is usually itching, redness or soreness. About 2 in 100 women have to stop using the patch because of skin irritation. Even though the patch sticks well most of the time, there is a possibility that it can become detached from the skin, either totally or partially. This is not common but can mean that its effectiveness as contraception can be lost. Despite its discreet design, some women still feel that the contraceptive patch can be seen. [https://patient.info/health/hormone-pills-patches-and-rings/contraceptive-patch](https://patient.info/health/hormone-pills-patches-and-rings/contraceptive-patch)
by Dr Rosemary Leonard MBE, MRCGP

Fibroids Q&A
Do fibroids shrink after menopause?
Dr Sarah Jarvis MBE Probably at least 1 in 2 women develop one or more fibroids in their lifetime, and probably more. They usually develop in women aged 30-50 and can sometimes run in families. [https://patient.info/health/periods-and-period-problems/fibroids](https://patient.info/health/periods-and-period-problems/fibroids)
by Dr Sarah Jarvis
Related patient information and medicines

Patient information leaflet
Mouth cancer
Epidermal growth factor receptor monoclonal antibody (EGFR mAb) is one form of targete... Cetuximab is an EGFR mAb. Tyrosine kinase inhibitors (TKIs) are another. Immunotherapy is treatment that aims to boost the body's own immune system to destroy the cancer cells. It is also sometimes called biological therapy: Recombinant interleukin (rIL-2) is.

Patient information leaflet
Myelofibrosis
Myelofibrosis is a condition affecting the bone marrow ... The gene mutation that occurs in most people affected by myelofibrosis is a mutation in Janus Kinase 2 (JAK2). Dr Sarah Jarvis, December 2021 NICE guidance on drug treatments for myelofibrosis Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis The National.

Patient information leaflet
Muscular dystrophy
Becker's muscular dy. Symptoms start in the teenage years or early 20s. The wea... Also, if a child has delayed motor milestones (as mentioned above), a doctor may advise testing for MD, even though the problem could be due to another cause. MD may be diagnosed using one or more of the following tests: A blood test Blood tests for creatine kinase.

Patient information leaflet
Primary liver cancer
Some conditions which cause persistent inflammation of the gut increase the risk slightly of developing an uncommon type of primary liver cancer (called. Smoking There is some evidence that smoking Smoking can increase the risk. There are new medicines being developed for the treatment of liver cancer. For example, sorafenib is a type of medicine.

Patient information leaflet
Glycogen storage disorders
Glycogen storage disorders are a group of inherited diseases. They result from a problem with one of the proteins (known as enzymes) involved in the conversion of glucose to glycogen, or the breakdown of glycogen back into glucose. They mostly tend to affect your liver and muscles. Most are diagnosed in childhood. Symptoms include weakness,.

Patient information leaflet
Juvenile idiopathic arthritis
As they are relatively new medicines, there are still studies being done to establish whether there are any long-term health risks from taking them. Options include: Etanercept Etanercept Tocilizumab Infliximab Abatacept Adalimumab Tofacitinib is another new drug. It belongs to a type of drug called JAK kinase inhibitors. It is sometimes used if.
Further reading and references
- pantothenate kinase 2; MedlinePlus, National Library of Medicine.
- Gordon N. Pantothenate kinase-associated neurodegeneration (Hallervorden-Spatz syndrome). Eur J Paediatr Neurol. 2002;6(5):243-7. doi: 10.1053/ejpn.2002.0606.
- Gregory A, Hayflick SJ. Neurodegeneration with brain iron accumulation. Folia Neuropathol. 2005;43(4):286-96.
- Hartig MB, Hortnagel K, Garavaglia B, Zorzi G, Kmiec T, Klopstock T, Rostasy K, Svetel M, Kostic VS, Schuelke M, Botz E, Weindl A, Novakovic I, Nardocci N, Prokisch H, Meitinger T. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol. 2006 Feb;59(2):248-56. doi: 10.1002/ana.20771.
- Hayflick SJ, Westaway SK, Levinson B, Zhou B, Johnson MA, Ching KH, Gitschier J. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med. 2003 Jan 2;348(1):33-40. doi: 10.1056/NEJMoa020817.
- Hayflick SJ. Pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome). J Neurol Sci. 2003 Mar 15;207(1-2):106-7. doi: 10.1016/s0022-510x(02)00433-1. No abstract available.
- Hayflick SJ. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr Opin Pediatr. 2003 Dec;15(6):572-7. doi: 10.1097/00008480-200312000-00005.
- Johnson MA, Kuo YM, Westaway SK, Parker SM, Ching KH, Gitschier J, Hayflick SJ. Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration. Ann N Y Acad Sci. 2004 Mar;1012:282-98. doi: 10.1196/annals.1306.023.
- Kotzbauer PT, Truax AC, Trojanowski JQ, Lee VM. Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J Neurosci. 2005 Jan 19;25(3):689-98. doi: 10.1523/JNEUROSCI.4265-04.2005.
- Ponka P. Hereditary causes of disturbed iron homeostasis in the central nervous system. Ann N Y Acad Sci. 2004 Mar;1012:267-81. doi: 10.1196/annals.1306.022.
- Zhang YM, Rock CO, Jackowski S. Biochemical properties of human pantothenate kinase 2 isoforms and mutations linked to pantothenate kinase-associated neurodegeneration. J Biol Chem. 2006 Jan 6;281(1):107-14. doi: 10.1074/jbc.M508825200. Epub 2005 Nov 3.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

